For Patients With Migraine, Are CGRP Inhibitors Worth the Cost?
January 19th 2019A recent review of the ICER report on calcitonin gene-related peptide inhibitor monoclonal antibodies has suggested that due to their cost and comparative benefit to available treatments, they should be reserved as second-line treatments.
Joseph Sullivan, MD: Scientifically Determining a Clinically Meaningful Change in Seizure Frequency
January 19th 2019The Director of the Pediatric Epilepsy Center at UCSF Benioff Children's Hospital spoke about what defines a "clinically meaningful change in seizure frequency" using data from a phase 3 clinical trial of ZX008 for the adjunctive treatment of seizures associated with Dravet syndrome.
Could Neuronal-Derived Exosomes Be Biomarkers of Treatment Target Engagement?
January 18th 2019This is the first biomarker evidence that peripherally administered exenatide may both engage and normalize brain insulin signaling in association with the activation of Akt and mTOR cascades in Parkinson disease.
Advancing Parkinson Disease Treatment By Building On What Works
January 17th 2019The director of Parkinson’s Disease and Movement Disorders Program at Henry Ford Hospital spoke about how improving levodopa delivery systems, among other advancements, has progressed the treatment of the disease.
In Myasthenia Gravis, Standard Assessments Alone Are Insufficient to Assess Dysphagia
January 15th 2019A small trial has suggested that patients with myasthenia gravis and dysphagia are not properly assessed by the common clinical scales for these swallowing problems and their risk of silent aspiration.
Dabigatran to be Assessed in Alzheimer Disease in BEACON Study
January 15th 2019The direct thrombin inhibitor is planned to be evaluated for its effect on the neurodegenerative disease in a trial of 40 to 60 patients with MCI and Alzheimer, led by researchers at the University of Rhode Island.
AHS Releases Position Statement on CGRP Inhibition Integration Into Clinical Practice
January 14th 2019The guidance provided the society’s recommendations for the use of the newly approved calcitonin gene-related peptide monoclonal antibodies for the prevention of migraine, among other guidance points.